Clinical Trials on Blood Coagulation Disorders

Total 200962 results

Novo Nordisk A/S

Recruiting

An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct

Haemophilia A

Canada
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of FVIII Gene Therapy for Hemophilia A

Hemophilia A

China
University of Texas Southwestern Medical Center

Recruiting

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Hemophilia A | Factor VIII

United States
Investigación en Hemofilia y Fisioterapia

Recruiting

Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia

Haemophilia

Spain
Octapharma

Recruiting

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients (Protect-NOW)

Haemophilia A

Belgium, Italy, United States, Azerbaijan, Belarus, Canada, Estonia, France, Germany, Hungary, Lithuania, Russian Federation, Spain, Turkey, United Kingdom, Mexico
Haemophilia Centre Rhine Main
Skane University Hospital; University of Bonn; Hopital Cardiologique Louis Pradel...

Recruiting

A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI

Haemophilia A

Germany
Novo Nordisk A/S

Available

Compassionate Use of Concizumab if You Have Haemophilia

Congenital Haemophilia

United States, Bulgaria, Sweden
BioMarin Pharmaceutical

Completed

A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A (SAAVY)

Hemophilia A

United States
CSL Behring

Active, not recruiting

Register of Patients With haEmophilia A tReated With Afstyla® (OPERA)

Haemophilia A

France
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
BioMarin Pharmaceutical

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3)

Hemophilia A

United States, Australia, Taiwan, Brazil
Novo Nordisk A/S

Completed

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities (THIRd)

Haemophilia A

Italy
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Haemophilia A

Japan
Pfizer

Completed

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Severe Hemophilia

China
Assistance Publique Hopitaux De Marseille

Completed

Occupational Integration of Adults With Severe Haemophilia in France: a Study Based on the FranceCoag Cohort (INTHEMO)

Severe Haemophilia

France
Novo Nordisk A/S

Terminated

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

Haemophilia A

Austria, Serbia, Bulgaria, United Kingdom, Germany, France, Turkey
Hospital Universitario La Fe

Unknown

Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients

Hemophilia A | Factor VIII

Spain
Universidad Católica San Antonio de Murcia

Unknown

Validation of Questionnaires HAL and HEP (VALIDATION)

Haemophilia

Spain
Beijing Children's Hospital

Unknown

Individualized Prophylaxis for Severe Hemophilia A Children

Hemophilia
Hospitales Universitarios Virgen del Rocío

Unknown

Hemostasis Profile in Patients With Severe Subarachnoid Hemorrhage

Coagulation Disorder | Subarachnoid Hemorrhage | Platelet Dysfunction

Spain
Sheba Medical Center

Unknown

Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders

Severe Hemophilia

Israel
Universiti Putra Malaysia

Completed

Effect of Resistance Training in Water Combined With Land on Starting and Turning ,12-weeks Resistance Training

Resistance, APC

China
Oregon Health and Science University
American Thrombosis and Hemostasis Network

Completed

Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders

Hemophilia A | Bleeding Disorder

United States
Cukurova University

Completed

Posture Analysis for Patients With Haemophilia

Hemophilia | Postural; Defect | Muscle Disorder

Turkey
K. C. Rasmussen

Completed

Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery

Disorders of Coagulation
Lee's Pharmaceutical Limited

Completed

Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

Coronary Heart Disease | Coagulation Disorder
BioMarin Pharmaceutical

Recruiting

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A (GENEr8-JPN)

Hemophilia A

Japan
BioMarin Pharmaceutical

Recruiting

A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)

Hemophilia A

Argentina
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

Hemophilia A

China
University Hospital, Bonn
Swedish Orphan Biovitrum

Recruiting

Sonography and Haemophilia

Haemophilia | Sonography

Germany
Spark Therapeutics

Completed

A Gene Transfer Study for Hemophilia A

Hemophilia A

United States, Australia, Canada, Israel, Thailand
BioMarin Pharmaceutical

Active, not recruiting

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (BMN 270-301)

Hemophilia A

United States, Taiwan, United Kingdom, Australia, Israel, Belgium, Brazil, France, Germany, Italy, Korea, Republic of, South Africa, Spain
Bayer

Completed

BAY81-8973 Pediatric Safety and Efficacy Trial

Haemophilia A

Spain, Russian Federation, United States, Hungary, Italy, Mexico, Norway, Romania, Bulgaria, Canada, Argentina, Denmark, Israel, Poland, Ireland, Latvia, Lithuania
Novo Nordisk A/S

Completed

A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge

Haemophilia A

Germany
Baxalta now part of Shire
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Active, not recruiting

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Hemophilia A

United States, Spain, Hungary, Italy, Germany, Austria, France
Assistance Publique Hopitaux De Marseille

Completed

Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia (TRANSHEMO)

Haemophilia

France
Bio Products Laboratory

Terminated

Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

Haemophilia A

Colombia, Germany, Poland
Hoffmann-La Roche

Completed

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Hemophilia A | Healthy Volunteers

China
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Haemophilia A

Poland
University of Pretoria
Novo Nordisk A/S; Medical Research Council, South Africa

Completed

Combining Registry Data in Haemophilia: TARGET H (TARGET-H)

Haemophilia
Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy...

Unknown

Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa (Thrombus)

Haemophilia

Poland
Bayer

Completed

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (OPTIMS)

Haemophilia A

France, Italy
Chulalongkorn University

Completed

Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A

Hemophilia A | Prophylaxis

Thailand
Centers for Disease Control and Prevention

Completed

Joint Outcome Study

Hemophilia A
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (pathfinder™6)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Australia, France, Thailand, Italy, Malaysia, Austria, Greece, Japan, Taiwan, Canada, Israel, Algeria, Argentina, Bulgaria, Germany, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding Disorder | Haemophilia B

United States, Sweden, Spain, Germany, United Kingdom, Denmark, France, Japan
Novo Nordisk A/S

Completed

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

Congenital Bleeding Disorder | Haemophilia B | Haemostasis

United States
Novo Nordisk A/S

Completed

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia (ACQUI-7)

Acquired Bleeding Disorder | Acquired Haemophilia

France
World Federation of Hemophilia

Completed

World Bleeding Disorders Registry Pilot Study (WBDR)

Hemophilia A and B

Clinical Trials on Blood Coagulation Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations